Nuvation Bio

NUVB · NYSE · United States

Share price · NUVB

$3.78-3.18 (-45.69%) 3M

close as of 2026-11-18 · 24h delayed · vol 6.0M (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NUVB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 5 Nov 2026-11.4%
  2. 2 Oct 2026-7.6%
  3. 20 Jul 2026+7.9%
  4. 25 Jun 2026-10.1%

    Nothing announced by NUVB that day or the session before.

  5. 4 Jun 2026+9.5%
  6. 3 Jun 2026-3.7%
  7. 1 Jun 2026+3.8%
  8. 5 May 2026+9.5%
  9. 3 Mar 2026-25.3%
  10. 12 Jan 2026-19.7%

Share of unusual movement by asset

For each asset, the share of NUVB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Taletrectinib
events and moves
167%
safusidenib
events and moves
6shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—13%
Sessions with no dated event—79%

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
ROS1Small molecule
Non-Small Cell Lung Cancer
ROS1-Positive Non-Small Cell Lung Cancer
Phase 3
Mutant IDH1Small molecule
Glioma

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
safusidenibPhase 3Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma …
Est. primary completion 2028-12-01 · NCT05303519 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
TaletrectinibPhase 3Non Small Cell Lung Cancer
Est. primary completion 2029-01 · NCT06564324 · CT.gov ↗
What to watch
May 2029 (1)
safusidenibPhase 3Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2, Oligodendroglioma …
Est. primary completion 2029-05 · NCT07712757 · CT.gov ↗
What to watch
2030 (2)
August 2030 (1)
TaletrectinibPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2030-08-30 · NCT07154706 · CT.gov ↗
What to watch
September 2030 (1)
safusidenibPhase 2Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma, Oligodendroglioma …
Est. primary completion 2030-09 · NCT07703436 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

4 January 2027FDA action dateTaletrectinibFDA target action date for IBTROZI sNDA
US, FDA · Source ↗

Recent

16 September 2026ApprovalTaletrectinibFDA approves IBTROZI supplemental application with updated duration of response
US, FDA · Nuvation Bio Inc. · Source ↗
29 June 2026Filing acceptedTaletrectinibUK MHRA validates taletrectinib MAA
UK, MHRA · Source ↗
June 2026Filing acceptedTaletrectinibMHRA validates taletrectinib marketing authorisation application
UK, MHRA · Nuvation Bio Inc. and Eisai · Source ↗
6 May 2026Filing acceptedTaletrectinibFDA accepts sNDA for IBTROZI with updated duration of response data
US, FDA · Source ↗
March 2026Filing acceptedTaletrectinibEMA validates taletrectinib marketing authorisation application
EU, EMA · Nuvation Bio Inc. and Eisai · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$45M$33M$154M+ $510M short-term inv.$42M-$39M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$32M$31M$259M+ $402M short-term inv.$63M-$43M operating cash flowreport ↗
2026-Q1$83M$35M$125M+ $408M short-term inv.—$5.1M operating cash flowreport ↗
2025-Q3$13M$29M$99M+ $450M short-term inv.$56M-$53M operating cash flowreport ↗
2025-Q2$4.8M$27M$248M+ $360M short-term inv.$59M-$48M operating cash flowreport ↗
2025-Q1$3.1M$25M$48M+ $414M short-term inv.$53M-$43M operating cash flowreport ↗
2024-Q3$0.7M$28M$30M+ $519M short-term inv.$41M-$31M operating cash flowreport ↗
2024-Q2$1.4M$29M$34M+ $543M short-term inv.$462M-$37M operating cash flowreport ↗
2024-Q1$0$13M$35M+ $562M short-term inv.$15M-$16M operating cash flowreport ↗
2023-Q3$0$19M$24M+ $595M short-term inv.$20M-$16M operating cash flowreport ↗
2023-Q2$0$19M$50M+ $581M short-term inv.$21M-$17M operating cash flowreport ↗
2023-Q1—$19M$30M+ $617M short-term inv.$22M-$19M operating cash flowreport ↗
2022-Q3—$21M$139M+ $535M short-term inv.$27M-$28M operating cash flowreport ↗
2022-Q2—$29M$102M+ $601M short-term inv.$35M-$27M operating cash flowreport ↗
2022-Q1—$21M$106M+ $632M short-term inv.$21M-$25M operating cash flowreport ↗
2021-Q3—$17M$345M+ $447M short-term inv.$22M-$13M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$63M$115M$164M+ $365M short-term inv.$51M-$173M operating cash flowreport ↗

For fiscal 2025, Nuvation Bio reported revenue of $62.902M, up 699.0% YoY, including $24.663M in net U.S. product revenue from IBTROZI and $38.239M in collaboration and license revenue. R&D expense was $115.106M, up 16.1% YoY. The company ended the period with cash and cash equivalents of $164.086M, and cash, cash equivalents, and marketable securities of $529.2M. Full-year net loss was $204.6M, or $0.60 per share.

Operationally, 216 new patients started IBTROZI in Q4 2025, bringing total new patient starts to 432 since launch in the second half of June 2025, with adoption roughly six times greater than prior recent ROS1 TKI launches based on IQVIA data. The company entered an exclusive license and collaboration agreement with Eisai in January 2026 for taletrectinib in Europe and additional countries outside the U.S., China, and Japan. Positive Phase 2 results for safusidenib in IDH1-mutant glioma showed an ORR of 44% and 88% progression-free at 24 months, and the first patient was enrolled in the pivotal Phase 3 SIGMA trial; Nuvation also received a $25M milestone payment from Nippon Kayaku in Q4.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$7.9M$99M$36M+ $467M short-term inv.$142M-$130M operating cash flowreport ↗
2023-FY—$71M$43M+ $569M short-term inv.$19M-$68M operating cash flowreport ↗
2022-FY—$88M$101M+ $560M short-term inv.$26M-$96M operating cash flowreport ↗
2021-FY—$69M$132M+ $633M short-term inv.$22M-$68M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($118K), 10 sales ($4.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-19Hattersley Gary · CHIEF SCIENTIFIC OFFICEROption exercise100,000$1.87$187KForm 4
2026-08-19Hattersley Gary · CHIEF SCIENTIFIC OFFICEROpen-market sale100,000$7.09$709KForm 4
2026-08-19Hattersley Gary · CHIEF SCIENTIFIC OFFICEROption exercise (derivative)100,000——Form 4
2026-07-15Sauvage Philippe · Chief Financial OfficerOption exercise39,999$2.17$87KForm 4
2026-07-15Sauvage Philippe · Chief Financial OfficerOption exercise1$1.97$2Form 4
2026-07-15Sauvage Philippe · Chief Financial OfficerOption exercise (derivative)39,999——Form 4
2026-07-15Sauvage Philippe · Chief Financial OfficerOption exercise (derivative)1——Form 4
2026-06-23Sauvage Philippe · Chief Financial OfficerOption exercise47,668$2.17$103KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 230 reporting institutions held 220.3M shares ($907.6M, 62.4% of shares outstanding).

#InstitutionSharesValue
1FMR LLC51,989,593$223.0M
2Decheng Capital LLC25,954,439$111.3M
3BlackRock, Inc.25,100,374$107.7M
4VANGUARD CAPITAL MANAGEMENT LLC11,626,198$49.9M
5Omega Fund Management, LLC8,081,089$34.7M
6Laurion Capital Management LP7,822,638$33.6M
7STATE STREET CORP6,784,927$29.1M
8GEODE CAPITAL MANAGEMENT, LLC5,863,654$25.2M
9BANK OF AMERICA CORP /DE/3,219,826$13.8M
10Redmile Group, LLC3,153,256$13.5M
11TANG CAPITAL MANAGEMENT LLC3,149,557$13.5M
12AMERICAN CENTURY COMPANIES INC2,897,078$12.4M
13TWO SIGMA INVESTMENTS, LP2,684,089$11.5M
14Jones Hill Capital LP2,383,031$10.2M
15VANGUARD PORTFOLIO MANAGEMENT LLC2,275,446$9.8M